Diabetes Reviews
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes
2019
-
A Glycemic Threshold Above Which the Improvement of β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Early Type 2 Diabetes: The Reversal of Glucotoxicity..
47:2017-2023.
2024
-
Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk.
47:259-266.
2024
-
Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
46:1524-1530.
2023
-
The Growing Role of Technology in the Care of Older Adults With Diabetes.
46:1455-1463.
2023
-
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
46:1046-1051.
2023
-
Comment on Duarte et al. Systematic Review and Network Meta-analysis of Neurostimulation for Painful Diabetic Neuropathy. Diabetes Care 2022;45:2466–2475.
46:e112-e112.
2023
-
Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial.
45:2862-2870.
2022
-
Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.
45:e146-e147.
2022
-
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study.
45:2152-2155.
2022
-
Enrollment of Black, Indigenous, and Other People of Color in Multicountry Randomized Controlled Trials of Diabetes Conducted in North America and Europe.
45:e116-e117.
2022
-
Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691.
45:e111-e112.
2022
-
Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.
45:684-691.
2022
-
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
45:547-554.
2022
-
Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial.
45:178-185.
2022
-
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.
44:2438-2444.
2021
-
Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters.
44:2212-2215.
2021
-
Oral Glucose Tolerance Test Results in Pregnancy Can Be Used to Individualize the Risk of Future Maternal Type 2 Diabetes Mellitus in Women With Gestational Diabetes Mellitus.
44:1860-1867.
2021
-
Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study.
44:1309-1316.
2021
-
Creating Composite Indices From Continuous Variables for Research: The Geometric Mean.
44:e85-e86.
2021
-
Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents.
44:e6-e8.
2021
-
HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.
44:290-296.
2021
-
Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial.
44:164-173.
2021
-
Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study.
43:3094-3101.
2020
-
White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries.
43:2643-2650.
2020
-
Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
43:2242-2247.
2020
-
Adolescent Obesity and Early-Onset Type 2 Diabetes.
43:1487-1495.
2020
-
Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study.
43:1553-1556.
2020
-
ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study.
43:835-842.
2020
-
Novel Biomarkers for Change in Renal Function in People With Dysglycemia.
43:433-439.
2020
-
Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood.
43:145-151.
2020
-
Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk.
42:1800-1808.
2019
-
The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study.
42:1159-1161.
2019
-
Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care.
42:1136-1146.
2019
-
Dysglycemia and the Density of the Coronary Vasa Vasorum.
42:980-982.
2019
-
Frailty and Risk of Fractures in Patients With Type 2 Diabetes.
42:507-513.
2019
-
Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial.
42:142-147.
2019
-
Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial.
41:2404-2413.
2018
-
A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.
41:1121-1124.
2018
-
Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.
41:348-355.
2018
-
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum.
41:14-31.
2018
-
Maturation of CGM and Glycemic Measurements Beyond HbA1c—A Turning Point in Research and Clinical Decisions.
40:1611-1613.
2017
-
Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications.
40:1500-1505.
2017
-
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin.
40:280-283.
2017
-
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 2016;39:1186–1201.
40:e23-e24.
2017
-
BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents.
39:1996-2003.
2016
-
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.
39:1915-1924.
2016
-
Making a Difference With Diabetes Research and Care.
39:1309-1310.
2016
-
Response to Comments on Fedorko et al. Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. Diabetes Care 2016;39:392–399.
39:e136-e137.
2016
-
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
39:1089-1100.
2016
-
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors’ Expert Forum.
39:1186-1201.
2016
-
Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE).
39:709-716.
2016
-
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.
39:701-708.
2016
-
Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study.
39:780-787.
2016
-
Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial.
39:392-399.
2016
-
Statement of Retraction. Nuts as a Replacement for Carbohydrates in the Diabetic Diet. Diabetes Care 2011;34:1706–1711. DOI: 10.2337/dc11-0338.
39:319-319.
2016
-
Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067–1074.
38:e170-e171.
2015
-
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
38:1558-1566.
2015
-
Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort.
38:793-800.
2015
-
Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial.
38:22-28.
2015
-
Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial.
37:3279-3285.
2014
-
The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.
37:3244-3252.
2014
-
Cognitive Function and the Risk for Diabetes Among Young Men.
37:2982-2988.
2014
-
Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults.
37:2989-2995.
2014
-
Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366.
37:e217-e217.
2014
-
Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366.
37:e223-e223.
2014
-
Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial.
37:1806-1814.
2014
-
Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial.
37:1721-1728.
2014
-
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia.
37:1360-1366.
2014
-
Response to Comment on Shah et al. Cardiovascular Complications and Mortality After Diabetes Diagnosis for South Asian and Chinese Patients: A Population-Based Cohort Study. Diabetes Care 2013;36:2670–2676.
37:e80-e80.
2014
-
Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study.
37:604-610.
2014
-
Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial.
37:634-643.
2014
-
Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes.
36:3599-3606.
2013
-
Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial.
36:2915-2922.
2013
-
Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922.
36:e181-e181.
2013
-
Cardiovascular Complications and Mortality After Diabetes Diagnosis for South Asian and Chinese Patients.
36:2670-2676.
2013
-
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events.
36:2466-2474.
2013
-
Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population.
36:2836-2842.
2013
-
Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial.
36:2162-2168.
2013
-
Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial.
36:1266-1271.
2013
-
Health Care Costs in People With Diabetes and Their Association With Glycemic Control and Kidney Function.
36:1172-1180.
2013
-
Effect of Fructose on Glycemic Control in Diabetes.
35:1611-1620.
2012
-
Absence of Disparities in the Quality of Primary Diabetes Care for South Asians and Chinese in an Urban Canadian Setting.
35:794-796.
2012
-
Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes.
35:787-793.
2012
-
Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes.
35:749-753.
2012
-
Screening for Dysglycemia in Overweight Youth Presenting for Weight Management.
35:711-716.
2012
-
Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit.
35:19-24.
2012
-
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes.
34:1902-1907.
2011
-
Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community.
34:1794-1798.
2011
-
Nuts as a Replacement for Carbohydrates in the Diabetic Diet.
34:1706-1711.
2011
-
Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal.
34:1265-1269.
2011
-
Lifestyle Interaction With Fat Mass and Obesity-Associated (FTO) Genotype and Risk of Obesity in Apparently Healthy U.S. Women.
34:675-680.
2011
-
Errata.
34:247-247.
2011
-
Ethnicity and Sex Affect Diabetes Incidence and Outcomes.
34:96-101.
2011
-
Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets.
33:2558-2560.
2010
-
Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study.
33:2250-2253.
2010
-
The Effect of Oral Antidiabetic Agents on A1C Levels.
33:1859-1864.
2010
-
Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.
33:1578-1584.
2010
-
Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance.
33:1629-1634.
2010
-
A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs.
33:1176-1178.
2010
-
Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes.
33:1379-1381.
2010
-
Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose.
33:608-613.
2010
-
Heterogeneous Effects of Fructose on Blood Lipids in Individuals With Type 2 Diabetes.
32:1930-1937.
2009
-
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
32:e58-e58.
2009
-
Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
32:915-920.
2009
-
Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors.
32:221-226.
2009
-
Dysglycemia and a History of Reproductive Risk Factors.
31:1635-1638.
2008
-
Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose.
31:1007-1014.
2008
-
A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events.
30:389-394.
2007
-
Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach.
30:432-434.
2007
-
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus.
30:162-172.
2007
-
The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes.
30:188-189.
2007
-
Metabolic Syndrome.
29:2471-2476.
2006
-
Diabetes During Diarrhea-Associated Hemolytic Uremic Syndrome.
28:2556-2562.
2005
-
Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects.
28:1630-1635.
2005
-
The Burden of Treatment Failure in Type 2 Diabetes.
28:761-762.
2005
-
Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control.
28:229-230.
2005
-
Telecare for Patients with Type 1 Diabetes and Inadequate Glycemic Control.
28:228-229.
2005
-
Comparative Roles of Microvascular and Nerve Function in Foot Ulceration In Type 2 Diabetes.
27:3026-3026.
2004
-
The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes.
27:2767-2767.
2004
-
Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control.
27:1088-1094.
2004
-
Utility of B-Type Natriuretic Peptide (BNP) as a Screen for Left Ventricular Dysfunction in Patients With Diabetes.
26:2081-2087.
2003
-
Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population.
26:290-296.
2003
-
The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada.
26:144-149.
2003
-
Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes.
25:1919-1927.
2002
-
A Randomized Trial of an Intervention to Improve Self-Care Behaviors of African-American Women With Type 2 Diabetes.
25:1576-1583.
2002
-
The Economic Cost of Diabetes in Canada, 1998.
25:1303-1307.
2002
-
Fasting Versus Postload Glucose Levels.
24:1855-1857.
2001
-
Cardiovascular and metabolic benefits of ACE inhibition: moving beyond blood pressure reduction..
23:882-883.
2000
-
Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators..
23 Suppl 2:B35-B39.
2000
-
Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction..
23:377-380.
2000
-
Is glucose a continuous risk factor for cardiovascular mortality?.
22:659-660.
1999
-
Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis..
22 Suppl 2:B35-B39.
1999
-
Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes..
22:191-197.
1999
-
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years..
22:233-240.
1999
-
Growth factors and the regulation of fetal growth..
21 Suppl 2:B60-B69.
1998
-
Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study.
19:1225-1228.
1996
-
Feasibility and Acceptability of a Proposed Infant Feeding Intervention Trial for the Prevention of Type I Diabetes.
18:940-942.
1995
-
Cow's Milk Exposure and Type I Diabetes Mellitus: A critical overview of the clinical literature.
17:13-19.
1994
-
Emphysematous Pyelonephritis: Complicated Urinary Tract Infection in Diabetes.
12:229-232.
1989
-
Stress-Free Labor for the Diabetic Parturient.
9:555-556.
1986
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)